PR-nCoV-mAbN
Warning: Last items in stock!
Availability date:
2019-nCoV N protein antibody
Recipient :
* Required fields
or Cancel
Immunogen/Antigen | SARS-CoV2 Nucleocapsid protein |
Background | N-protein, being one of the predominantly expressed proteins at the early stage of SARS-CoV infection, against which a strong antibody response is initiated by the host; has been proposed to be an attractive diagnostic tool.In serum of SARS-CoV patients, the N-protein has been detected as early as day 1 of infection by ELISA using monoclonal antibodies against it. Furthermore, a comparative study to detect SARS-CoV specific IgG, SARS-CoV RNA, and the N-protein during early stages of infection has demonstrated that detection efficiency of the N-protein is significantly higher than the other two markers. N-protein has been one of the top target for development of IgM ELISA for diagnostic purpose. N-protein has also been tested in its use as a protective vaccine against SARS-CoV infection. So it could be a potential vaccine candidate in the effort to develop an efficient vaccine against 2019-nCov/COVID. |
Reactivity | COVID-19 N protein |
Formulation | Lyophilized powder in 0.01M PBS, pH 7.4. |
Host Species | Mouse |